Product Name:    Upadacitinib

Synonyms:    Upadacitinib;ABT-494;ABT-494(Upadacitinib) free base;Upadacitinib (ABT-494);ABT-494 (Upadacitinib);Upadacitinib (Rinvoq);ABT-494; ABT494; ABT 494;CS-2730

CAS:    1310726-60-3

MF:    C17H19F3N6O

MW:    380.37

EINECS:    213-161-9

Upadacitinib is a JAK1 inhibitor (IC50 = 47 nM). It is selective for JAK1 over JAK3 and tyrosine kinase 2 (Tyk2; IC50s = 2,304 and 4,690 nM, respectively), as well as a panel of 83 additional kinases at 1 μM, but does inhibit JAK2, Rho-associated kinase I (ROCK1), and ROCK2 (IC50s = 120, 920, and 430 nM, respectively). Upadacitinib decreases cytokine-induced STAT phosphorylation in a variety of human cells with IC50 values ranging from 1.6 to 649 nM. It reduces M. tuberculosis-induced paw swelling and bone erosion in a rat model of arthritis when administered at doses of 1, 3, and 10 mg/kg twice per day for 17 days. Formulations containing upadacitinib have been used in the treatment of rheumatoid arthritis.